

**COUNCIL OF EUROPE**  
**European Directorate for the Quality of Medicines & HealthCare**  
**OMCL NETWORK QUALITY MANAGEMENT SYSTEM**

**ATTESTATION**

The EDQM, European Directorate for the Quality of Medicines & HealthCare, hereby declares that

**Finnish Medicines Agency, Fimea, Laboratory**

Address: Mannerheimintie 166, 00034 Helsinki, Finland

**Section audited: Pharmaceutical, Chemical, Biological, Microbiological**

has been audited in accordance with the EDQM instruction *ISO7/02* on the OMCL Network Mutual Joint Audit Scheme.

The above-mentioned OMCL is entitled to declare that it has satisfactorily implemented a Quality Management System in accordance with *ISO/IEC 17025*, with the relevant texts of the *European Pharmacopoeia*, with the *Quality Management Guidelines* and the *Terms of Reference* of the General European OMCL Network.

Detailed information can be found in the Audit Report, which is consigned in document ***PA/PH/OMCL-QA (20) 06 DEF*** and the Follow-up Report ***PA/PH/OMCL-QA (20) 20 DEF*** corresponding to the ***MJA 01/20***, as well as in the enclosed Scope of Assessment. The original documents are archived at the Department of Biological Standardisation, OMCL Network & HealthCare (DBO) of the EDQM and the Director of the OMCL has received a certified copy.

Attestation number: ***EDQM/MJA-160***

Strasbourg, 2 October 2020

Valid until: ***3 February 2024***

Laurent Mallet, Ph.D.

Head of DBO, EDQM

**EUROPEAN NETWORK OF OFFICIAL MEDICINES CONTROL LABORATORIES**  
**SCOPE OF ASSESSMENT OF MJA 01/20**



**SCOPE OF ASSESSMENT of MJA 01/20**

Page 2 of 3

<b>SCOPE OF ASSESSMENT</b>		
<b>Products/materials tested</b>	<b>Type of test</b>	<b>Test methods</b> (where applicable, reference is made to the corresponding Ph. Eur. General Method)
<p><b>Chemicals</b></p> <p>Active Pharmaceutical Ingredients (API) x                      Pharmaceutical finished dosage forms x                      Pharmaceutical excipients</p>	<p>Assay, identification and purity tests by means of high performance liquid chromatography (HPLC, detection UV/VIS)</p> <p>Determination of water by means of Karl-Fischer semi-micro-method</p> <p>Determination of water by means of Karl-Fischer micro-method</p> <p>Assay, identification and purity tests by means of UV/VIS-absorption</p> <p>Potentiometric determination of pH-values</p> <p>Clarity and degree of opalescence</p> <p>Degree of coloration of liquids</p> <p>Particulate contamination: sub-visible particles</p>	<p>In-house method based on test of the European Pharmacopoeia<sup>1)</sup></p> <p>2.2.29</p> <p>2.2.46</p> <p>2.5.12</p> <p>2.5.32</p> <p>2.2.25</p> <p>2.2.3</p> <p>2.2.1</p> <p>2.2.2</p> <p>2.2.19</p>
	<p><b>Pharmaceutical-technological</b></p> <p>Dissolution test for solid dosage forms</p>	<p>2.9.3</p> <p>In-house method based on test of the European Pharmacopoeia<sup>1)</sup></p>
<p><b>Biologicals</b></p> <p>Biological and biotech human and veterinary products</p>	<p>Identification and purity tests by electrophoresis</p> <p style="padding-left: 20px;">- SDS-PAGE</p> <p>Potency/antigen quantification by means of ELISA</p> <p>Potency assay</p> <p style="padding-left: 20px;">- cell culture/ cell based assay</p>	<p>2.2.31</p> <p>2.7.1</p>

**EUROPEAN NETWORK OF OFFICIAL MEDICINES CONTROL LABORATORIES**  
**SCOPE OF ASSESSMENT OF MJA 01/20**



**SCOPE OF ASSESSMENT of MJA 01/20**

Page 3 of 3

<b>SCOPE OF ASSESSMENT</b>		
<b>Products/materials tested</b>	<b>Type of test</b>	<b>Test methods</b> (where applicable, reference is made to the corresponding Ph. Eur. General Method)
<i>Chemicals</i> x	<b>Microbiological tests:</b> Sterility Microbiological examination of non-sterile products (total viable aerobic count) Microbiological examination of non-sterile products (test for specified micro-organisms) Bacterial endotoxins	2.6.1 2.6.12 2.6.13 2.6.14 -Gel-clot -Kinetic chromogenic
<i>Biologicals</i> x		

**Remarks:**

The following test was removed from the scope due to missing raw data:

- Identification and purity tests by electrophoresis: - IEF